Next Article in Journal
Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?
Previous Article in Journal
Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
Open AccessArticle

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry

1
Blood and Cancer Biology Laboratory, Department of Molecular Medicine & Pathology, School of Medical Sciences, The University of Auckland, Auckland 1023, New Zealand
2
Department of Pathology and Laboratory Medicine, Auckland City Hospital, Auckland 1023, New Zealand
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Curr. Oncol. 2021, 28(2), 1544-1557; https://doi.org/10.3390/curroncol28020146
Received: 5 March 2021 / Revised: 15 April 2021 / Accepted: 16 April 2021 / Published: 18 April 2021
(This article belongs to the Section Hematology)
Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic data for PV, ET and PMF collected by the New Zealand Cancer Registry (NZCR) between 2010 and 2017. Results: We found that the NZCR capture rates were lower than average international incidence rates for PV and ET, but higher for PMF (0.76, 0.99 and 0.82 per 100,000, respectively). PV patients were older and had worse outcomes than expected, which suggests these patients were reported to the registry at an advanced stage of their disease. Polynesian patients with all MPN subtypes, PV, ET and PMF, were younger than their European counterparts both at the time of diagnosis and death (p < 0.001). Male gender was an independent risk factor for mortality from PV and PMF (hazard ratios (HR) of 1.43 and 1.81, respectively; p < 0.05), and Māori ethnicity was an independent risk factor for mortality from PMF (HR: 2.94; p = 0.006). Conclusions: New Zealand Polynesian patients may have increased genetic predisposition to MPN, thus we advocate for modern genetic testing in this ethnic group to identify the cause. Further work is also required to identify modifiable risk factors for mortality in MPN, in particular those associated with male gender and Māori ethnicity; the results may benefit all patients with MPN. View Full-Text
Keywords: myeloproliferative neoplasms; polycythaemia vera; essential thrombocythaemia; primary myelofibrosis; epidemiology; incidence rates; capture rates; survival; ethnic disparity; cancer myeloproliferative neoplasms; polycythaemia vera; essential thrombocythaemia; primary myelofibrosis; epidemiology; incidence rates; capture rates; survival; ethnic disparity; cancer
Show Figures

Figure 1

MDPI and ACS Style

Varghese, C.; Immanuel, T.; Ruskova, A.; Theakston, E.; Kalev-Zylinska, M.L. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry. Curr. Oncol. 2021, 28, 1544-1557. https://doi.org/10.3390/curroncol28020146

AMA Style

Varghese C, Immanuel T, Ruskova A, Theakston E, Kalev-Zylinska ML. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry. Current Oncology. 2021; 28(2):1544-1557. https://doi.org/10.3390/curroncol28020146

Chicago/Turabian Style

Varghese, Chris; Immanuel, Tracey; Ruskova, Anna; Theakston, Edward; Kalev-Zylinska, Maggie L. 2021. "The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry" Curr. Oncol. 28, no. 2: 1544-1557. https://doi.org/10.3390/curroncol28020146

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop